Journal
OPHTHALMOLOGY
Volume 124, Issue 11, Pages S27-S33Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2017.07.022
Keywords
-
Categories
Funding
- NEI/NIH [EY01792, R01 EY024349-01A1]
- Research to Prevent Blindness (RPB)
- Career Development Award from RPB
Ask authors/readers for more resources
Dry eye disease (DED) represents a heterogeneous group of conditions with tear film insufficiency and signs and/or symptoms of ocular surface irritation. The clinical manifestations of DED can be highly variable; hence the diagnosis is often based on a combination of symptoms, signs, and clinical tests, given that any one of these alone would miss a significant number of patients. Similarly, the treatment must often be tailored to each patient by targeting the specific mechanisms involved in his or her disease. The purpose of this review is to summarize recent advances that have allowed us to better recognize, categorize, and treat patients with DED. The most notable new diagnostic tests in DED are tear film osmolarity, inflammatory biomarkers, and meibomian gland imaging. Therapeutically, anti-inflammatory therapy, meibomian gland heating and expression, and scleral contact lenses are some of the latest options available for treating DED. (C) 2017 by the American Academy of Ophthalmology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available